MB101 is a proprietary humanized, monoclonal antibody directed against an undisclosed target and is manufactured under recombinant conditions in a mammalian cell line (CHO cells).
“This is a major achievement for Miltenyi Biotec and the MB101 project team. By receiving the manufacturing license, we have finalized an essential project milestone for our clinical trial material of MB101 “, explained Dr. Ulf Bethke, Global Head Clinical Products. “MB101 is a promising candidate within our therapeutic antibody development pipeline, for which we are currently preparing a clinical Phase I study scheduled to begin in the 2nd half of 2013.”
As a fully integrated biopharmaceutical company, Miltenyi Biotec executed all key MB101 project activities in house, including antibody engineering and humanization, cell line development, GMP-compliant manufacturing of drug substance and drug product, QC testing, antibody characterization, and stability studies.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research to clinical applications. Scientists and clinicians around the world use Miltenyi Biotec’s enabling technologies for effective sample preparation, cell isolation, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The MACS(R) brand has set standards in the industry and is trusted across basic, translational and clinical research settings. Miltenyi Biotec entertains a clinical development portfolio in cellular therapy and is currently under regulatory review of its HDE filing at the US FDA for treatment of AML. Miltenyi Biotec has 1,400 employees in 22 countries.
